Predictors of Mortality in Tocilizumab-Treated Severe COVID-19

Purpose: Tocilizumab is associated with positive outcomes in severe COVID-19. We wanted to describe the characteristics of nonresponders to treatment. Methods: This was a retrospective multicenter study in two respiratory departments investigating adverse outcomes at 90 days from diagnosis in subjec...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagkratis, Konstantinos, Chrysikos, Serafeim, Antonakis, Emmanouil, Pandi, Aggeliki, Kosti, Chrysavgi Nikolaou, Markatis, Eleftherios, Hillas, Georgios, Digalaki, Antonia, Koukidou, Sofia, Chaini, Eleftheria, Afthinos, Andreas, Dimakou, Katerina, Papanikolaou, Ilias C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230711/
https://www.ncbi.nlm.nih.gov/pubmed/35746585
http://dx.doi.org/10.3390/vaccines10060978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230711/
https://www.ncbi.nlm.nih.gov/pubmed/35746585
http://dx.doi.org/10.3390/vaccines10060978

Ejemplares similares